5/29/2025

Megestrol Acetate Tablets

Products Affected - Description

- Megestrol acetate oral tablet, Major, 40 mg, unit-dose blister pack, 100 count, NDC 00904-7236-61
- Megestrol acetate oral tablet, Strides Pharma, 20 mg, bottle, 100 count, NDC 64380-0158-01
- Megestrol acetate oral tablet, Strides Pharma, 40 mg, bottle, 100 count, NDC 64380-0159-01
- Megestrol acetate oral tablet, Strides Pharma, 40 mg, bottle, 500 count, NDC 64380-0159-03
- Megestrol acetate oral tablet, Teva, 20 mg, bottle, 100 count, NDC 00555-0606-02
- Megestrol acetate oral tablet, Teva, 40 mg, bottle, 100 count, NDC 00555-0607-02

Reason for the Shortage

- Major did not provide a reason for the shortage.
- Strides did not provide a reason for the shortage.
- Teva did not provide a reason for the shortage.

Available Products

- There are no presentations available

Estimated Resupply Dates

- Strides has megestrol acetate 20 mg tablets in 100 count bottles and 40 mg tablets in 100 count and 500 count bottles on back order and the company estimates a release date of June 2025.
- Major has megestrol acetate 40 mg tablets in unit-dose packs on back order and the company estimates a release date of mid-June 2025.
- Teva has megestrol acetate 20 mg tablets in 100 count and 40 mg tablets in 100 count bottles on back order and the company estimates a release date of mid-July 2025.

Updated

Updated May 29, 2025 by Michelle Wheeler, PharmD, Drug Information Specialist. Created May 23, 2025 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2025, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.